Chronic Hepatitis B, C Linked With Lymphoma in HIV Patients

Article

This Medical News Minute examines a recent report that found that chronic infection with hepatitis B or C virus was associated with an increased risk for lymphoma among HIV patients on antiretroviral therapy.

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara examines a new study that found that chronic infection with hepatitis B or C virus was associated with an increased risk for non-Hodgkin lymphoma among HIV patients on antiretroviral therapy.

Among treatment-naive patients, the hazard ratio (HR) for non-Hodgkin lymphoma with hepatitis B was 1.33 (95% CI, 0.69–2.56) and with hepatitis C was 0.67 (95% CI, 0.40–1.12). Among treated patients, the HR with hepatitis B was 1.74 (95% CI, 1.08–2.82) and with hepatitis C was 1.73 (95% CI, 1.21–2.46).

Recent Videos
4 experts in this video
7 experts are featured in this series.
2 KOLs are featured in this series.
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
2 experts are featured in this series.
2 experts are featured in this series.
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
Related Content
The phase 3 KEYNOTE-689 trial showed a median EFS of 59.7 months with the pembrolizumab regimen in locally advanced head and neck squamous cell carcinoma.

Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group

Tim Cortese
October 29th 2025
Article

The phase 3 KEYNOTE-689 trial showed a median EFS of 59.7 months with the pembrolizumab regimen in locally advanced head and neck squamous cell carcinoma.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Explore the promising role of antibody-drug conjugates targeting TROP2 in treating metastatic triple-negative breast cancer and improving patient outcomes.

3 Things You Should Know About Single-Agent ADCs in TNBC Treatment

ONCOLOGY Staff
October 29th 2025
Article

Explore the promising role of antibody-drug conjugates targeting TROP2 in treating metastatic triple-negative breast cancer and improving patient outcomes.

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Anne Chiang, MD
October 20th 2025
Podcast

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

SCT with Melphalan/Ascorbic Acid Safe for BRCA-Mutated PDAC

SCT with Melphalan/Ascorbic Acid Safe for BRCA-Mutated PDAC

Ariana Pelosci
October 28th 2025
Article

Results from the SHARON trial presented at ESMO 2025 showed a potential treatment option for patients with PDAC who have BRCA1/2 or PALB2 mutations.

The developers will present these data at an upcoming medical meeting and plan to begin discussions with regulatory authorities.

Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC

Tim Cortese
October 28th 2025
Article

Belzutifan/lenvatinib also showed a favorable trend toward improvement for overall survival in this advanced renal cell carcinoma population.